Findings provide further evidence of benefit for combined use of erlotinib and bevacizumab.

The BELIEF (Bevacizumab and erlotinib in EGFR mut+ NSCLC) international trial aims to determine the long-term outcome of patients with advanced non-squamous NSCLC with activating EGFR mutations and treated with the combination of erlotinib and bevacizumab.

109 patients were enrolled at 29 centres in eight European countries.

Findings show that the overall progression-free survival was 13.2 months and provides further evidence of benefit for the combined use of these drugs in patients with NSCLC with activating EGFR mutations.

Published in The Lancet in May 2017 with summary free to read.